Nimodipine for aneurysmal subarachnoid hemorrhage 

All patients should be given enteral (through PO or NGT) nimodipine (dhCCP) within 48 hours of symptom onset in subarachnoid hemorrhage
→ reduces the risk of delayed cerebral ischemia, improves outcomes in SAH
Mechanism
Reduces risk of cerebral vasospasm
+/- Neuroprotection via dilation of small arteries not visible on angiograms
+/- Reduction of Ca-dependant excitotoxicity
+/- Diminished platelet aggregation
+/- Inhibition of ischemia triggered by RBC lysis products
IV nimodipine is associated with serious adverse events, including death